Qulipta Tablet
Product Images NDC 0074-7095
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Qulipta (NDC 0074-7095). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Abbvie Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Change From Baseline In Monthly Migraine Days In Study 1 (Qulipta 02)
Figure 2: Distribution Of Change From Baseline In Mean Monthly Migraine Days By Treatment Group In Study 1 (Qulipta 03)
Diagramdescription Automatically Generated (Qulipta 04)
Chart, Bar Chartdescription Automatically Generated (Qulipta 05)
Figure 5: Change From Baseline In Monthly Migraine Days In Study 3 (Qulipta 06)
Figure 6: Distribution Of Change From Baseline In Mean Monthly Migraine Days By Treatment Group In Study 3 (Qulipta 07)
Principal Display Panelndc 0074-7095-30rx Onlyqulipta®(atogepant) Tablets10 mgcontains 30 Tablets (Qulipta 08)
Principal Display Panelndc 0074-7096-30rx Onlyqulipta®(atogepant) Tablets30 mgcontains 30 Tablets (Qulipta 09)
Principal Display Panelndc 0074-7094-30rx Onlyqulipta®(atogepant) Tablets60 mgcontains 30 Tablets (Qulipta 0a)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.